Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 14/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 12/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672510 | 0.88 | TDP1 (0.57) | HCRTR2HCRTR1POLBTDP1NNMT | |
| SCHEMBL17449208 | 0.84 | HCRTR2 (0.45) | HCRTR2HCRTR1POLBTDP1NNMT | |
| SCHEMBL17069767 | 0.84 | HCRTR2 (0.45) | HCRTR2HCRTR1POLBTDP1NNMT | |
| SCHEMBL19315148 | 0.75 | HCRTR2 (0.39) | HCRTR2HCRTR1POLBTDP1NNMT | |
| SCHEMBL16828321 | 0.73 | HCRTR2 (0.56) | HCRTR2HCRTR1 | |
| SCHEMBL31141991 | 0.73 | POLB (0.73) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL15308663 | 0.73 | NNMT (0.71) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL8443874 | 0.73 | POLB (0.73) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL27248156 | 0.71 | POLB (0.51) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL16025487 | 0.71 | POLB (0.51) | HCRTR2HCRTR1POLBTDP1NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745284-B2 | 2-pyridyloxy-4-ether orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9725434-B2 | Hydroxy-substituted orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9586950-B2 | 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586934-B2 | 2-pyridyloxy-4-methyl orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9556145-B2 | 2-pyridyloxy-4-ester orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160368898-A1 | 2-PYRIDYLOXY-4-METHYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160304490-A1 | 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160068510-A1 | HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068514-A1 | HALO AND TRIFLUOROMETHYL SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160016935-A1 | 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20150252033-A1 | 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252033-A1 | 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885HCRTR1 2/4885POLB 4783/4885 |
| US-20160068510-A1 | HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | HCRTR2 1/4885HCRTR1 2/4885POLB 4788/4885 |
| US-20160068514-A1 | HALO AND TRIFLUOROMETHYL SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | HCRTR2 1/4885HCRTR1 2/4885POLB 4648/4885 |
| US-20160304490-A1 | 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | HCRTR2 1/4885HCRTR1 2/4885POLB 4788/4885 |
| US-20160368898-A1 | 2-PYRIDYLOXY-4-METHYL OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR2 1/4885HCRTR1 2/4885POLB 4626/4885 |
| US-20160016935-A1 | 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR2 1/4885HCRTR1 2/4885POLB 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.